Results 171 to 180 of about 18,145 (196)

Ranibizumab for myopic choroidal neovascularization

Expert Opinion on Biological Therapy, 2020
Introduction: Myopic choroidal neovascularization (CNV) is one of the most vision-threatening complications in patients with pathologic myopia. Over the last decade, anti-angiogenesis therapy with anti-vascular endothelial growth factor (anti-VEGF ...
Danny Ng, Nicholas Fung, Timothy Y Y Lai   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Ranibizumab

Reactions Weekly, 2019
  +4 more sources

Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation

Ophthalmology and Therapy, 2021
Dhanashree Ratra
exaly  

Ranibizumab for the treatment of diabetic retinopathy

Expert Opinion on Biological Therapy, 2021
Irini Chatziralli
exaly  

Ranibizumab

Reactions Weekly, 2022
  +4 more sources

Ranibizumab

Drugs of the Future, 2003
null Sorbera, L.A., null Leeson, P.A., null Bayes, M.   +2 more
openaire   +1 more source

Ranibizumab

Reactions Weekly, 2014
openaire   +2 more sources

Ranibizumab

Reactions Weekly, 2016
  +4 more sources

Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity

Acta Ophthalmologica, 2020
Jianhong Liang, Jianhong Liang
exaly  

Ranibizumab

Reactions Weekly, 2009
openaire   +1 more source